HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

mouse pRL1a protein

Also Known As:

pRL1a protein, mouse; IPGLPLSL; Ile-Pro-Gly-Leu-Pro-Leu-Ser-Leu; isoleucyl-prolyl-glycyl-leucyl-prolyl-leucyl-seryl-leucine

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Biological Factors: 2472
- Antigens: 143924
  - Neoplasm Antigens: 6217
    - mouse pRL1a protein: 3
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - mouse pRL1a protein: 3

Experts

1.	Nakayama, Eiichi: 1 article (11/2003)
2.	Uenaka, Akiko: 1 article (11/2003)

Related Diseases

1.	Leukemia 08/01/1997 - "Cytotoxic T lymphocytes (CTL) generated in (BALB/c x C57BL/6)F1 (CB6F1) and BALB/c spleen cells stimulated with BALB/c radiation-leukemia RL Male 1 cells or pRL1a (IPGLPLSL) peptide itself recognized pRL1a on RL Male 1 in association with Ld. " 11/01/2003 - "We identified a unique tumor antigen peptide pRL1a, IPGLPLSL that is recognized by CTL on BALB/c RL male 1 leukemia by peptide elution. " 05/01/1998 - "pRL1a (IPGLPLSL) is the Ld-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL(male)1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. "
2.	Neoplasms (Cancer) 05/01/1998 - "pRL1a (IPGLPLSL) is the Ld-binding tumor rejection antigen peptide recognized by CTLs on BALB/c radiation leukemia RL(male)1. We demonstrated that in vivo and in vitro sensitization with pRL1a multiple antigen peptide (MAP), but not with the pRL1a peptide itself, generated pRL1a-specific CTLs in the spleen cells of BALB/c mice. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Neoplasm Antigens (Tumor Antigens)
3.	Antigens